ArticleCancers2021

First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes.

David Lang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.